Skip to main content
Download PDF

PET-based radiomics visualizes tumor-infiltrating CD8 T cell exhaustion to optimize radiotherapy/immunotherapy combination in mouse models of lung cancer

Biomarker Research volume 11, Article number: 10 (2023) Cite this article

Abstract

Background

Cumulative preclinical and clinical evidences showed radiotherapy might augment systemic antitumoral responses to immunotherapy for metastatic non-small cell lung cancer, but the optimal timing of combination is still unclear. The overall infiltration and exhausted subpopulations of tumor-infiltrating CD8+ T cells might be a potential biomarker indicating the response to immune checkpoint inhibitors (ICI), the alteration of which is previously uncharacterized during peri-irradiation period, while dynamic monitoring is unavailable via repeated biopsies in clinical practice.

Methods

Basing on tumor-bearing mice model, we investigated the dynamics of overall infiltration and exhausted subpopulations of CD8+ T cells after ablative irradiation. With the understanding of distinct metabolic characteristics accompanied with T cell exhaustion, we developed a PET radiomics approach to identify and visualize T cell exhaustion status.

Results

CD8+ T cell infiltration increased from 3 to 14 days after ablative irradiation while terminally exhausted populations significantly predominated CD8+ T cells during late course of this infiltrating period, indicating that 3–7 days post-irradiation might be a potential appropriate window for delivering ICI treatment. A PET radiomics approach was established to differentiate T cell exhaustion status, which fitted well in both ICI and irradiation settings. We also visualized the underlying association of more heterogeneous texture on PET images with progressed T cell exhaustion.

Conclusions

We proposed a non-invasive imaging predictor which accurately assessed heterogeneous T cell exhaustion status relevant to ICI treatment and irradiation, and might serve as a promising solution to timely estimate immune-responsiveness of tumor microenvironment and the optimal timing of combined therapy.

Introduction

Combination of radiotherapy (RT) and immune checkpoint inhibitors (ICI) therapy has demonstrated its great potential to improve the treatment outcome of patients with advanced non-small cell lung cancer (NSCLC) [1,2,3,4]. While the optimal timing and pattern of combination treatments is still unclear, and reliable biomarkers to select patients who would benefit most from the RT/ICI combination treatments are urgently needed [5].

The infiltration abundance of tumor-infiltrating lymphocytes (TILs), especially CD8+ T cells, in tumor microenvironment (TME) has been found to be a potential biomarker of response to ICI or prognosis [6,7,8,9]. Evidence showed that the infiltration density of CD8+ TILs may experience alteration during peri-irradiation period, which is closely correlated with the prognosis and pathologic response after chemoradiotherapy [10]. Therefore, biomarkers based on baseline level or few time points may be insufficient to provide precise guidance to clinical strategies.

Moreover, as antigens persist in tumors, CD8+ T cells may differentiate into a special state known as T cell exhaustion [11]. Exhausted CD8+ T cells (Tex) exhibit progressive loss of effector functions and high expression of inhibitory receptors, such as PD-1, TIM-3 and so on [12, 13], which dampen effector immunity and cause poor responsiveness to ICI therapy. Early-exhausted T cells (early Tex) with intermediate expression of PD-1(PD-1int) can be reinvigorated by blockade of the PD-1 pathway whereas terminally-exhausted T cells (terminal Tex) with high expression of PD-1(PD-1hi) cannot [12]. Recent evidence indicates that the proportion of early Tex versus terminal Tex was associated with the prognosis of patients with NSCLC, and might allow to identify patients who may benefit from PD-1 blockade or combined therapies [14] [15]. Therefore, dynamic monitoring of both the overall infiltration abundance and the proportion of different functional subpopulations of CD8+ T cells during peri-irradiation period might be a promising and efficient approach to indicate the ICI responders as well as the timing of combining ICI therapy with RT.

However, the invasiveness of repeated biopsies and sampling bias due to the heterogeneity of tumors bring great difficulties to acquire dynamic biomarkers based on histopathological level. Radiomics, a noninvasive “digital biopsy” technique, which extracts quantitative features from medical images to correlate with biological characteristics of tumors, might provide a solution [16]. Radiomics approaches have been developed to evaluate the prognosis in various tumors [17,18,19,20,21], and even to predict tumor-infiltrating CD8+ cells, response to ICI therapy and abscopal response of combining ICI therapy with RT [22, 23]. Since exhausted T cells have been reported to exhibit metabolic insufficiency with suppressed glycolysis and restricted glucose uptake [24, 25], we assumed that metabolic characteristics of Tex might be reflected by radiomic features of 18FDG-PET.

Here, basing on tumor-bearing mice model, we aimed to investigate the dynamics of overall infiltration and functional subpopulations of CD8+ T cells after ablative irradiation, and to develop a PET radiomic approach to identify and visualize the level of T cell exhaustion.

Methods and materials

Cell lines

The murine Lewis lung carcinoma (LLC) cells and B16 melanoma cells were purchased from the National Collection of Authenticated Cell Cultures (Shanghai, China). Cells were cultured in RPMI Medium 1640 (Gibco), which contained 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Hyclone). Cells were incubated at 37℃ in 5% CO2.

Tumor models and treatments

Female C57BL/6 N mice between six to eight weeks old were purchased from Zhejiang Vital River Laboratory Animal Technology Co. Ltd (Jiaxing, Zhejiang, China) and were maintained under specific pathogen-free (SPF) conditions, with the temperature of 20 ~ 25℃, humidity of 40% ~ 70%, and the light time set from 8:00 to 20:00.

To establish tumor models, 1 M LLC or 0.5 M B16 cells were inoculated subcutaneously into the right flank of mice. Treatment was started when average tumor volume reached 200mm3 (10 days after inoculation, defined as D0). Mice were randomized to receive irradiation at D0 (RT group) or 200 μg anti-PD-L1(10F.9G2, BioXcell) antibody i.p. since D7, every 3 days for 5 times (ICI group). Three mice per group per interested time point were used in each of the three independent experiments. All mice experiments were ethically approved by the Institutional Animal Care and Use Committee of Shanghai Chest Hospital.

Irradiation

Mice were anesthetized and positioned in the prone orientation. A CT scan was acquired and treatment planning was performed using Monte Carlo algorithm. Dose-volume histogram evaluation showed the target volume receiving 95% ~ 105% of the dose. Radiation was delivered using a 6MV X-ray linear accelerator at a dose rate of 600 cGy/min.

Micro-PET/CT

For RT group, micro-PET/CT was performed on D0, D3, D7, D14 and D21. While for ICI group, micro-PET/CT was performed on D0, D7 (before anti-PD-L1 treatment) and D22 (after anti-PD-L1 treatment). Mice were injected intraperitoneally with 5.55 MBq 18F-FDG in 0.1 mL saline. After an hour, micro-PET/CT images were acquired using an Inveon micro-PET/CT scanner (Siemens Preclinical Solution). During scanning period, mice were maintained under 2% isoflurane anesthesia and were placed in the prone position on the bed of the scanner. CT scans were performed first (Voltage: 80 kV, Current: 500μA, Exposure 300 ms, Projections: 120, effective pixel size: 112.85 μm). Then, PET scans were performed 10 min later, OSEM3D/SP-MAP algorithm (2 OSEM iterations, 18 MAP iterations, target resolution 1.5 mm and matrix size: 128 × 128) without filtering and smoothing was used to reconstruct PET images. The PET images were converted into SUV units by normalizing the activity concentration to the dosage of injected 18F-FDG and mouse body weight. The micro-PET and CT images were generated separately and then fused using Inveon Research Workplace (Siemens Preclinical Solution).

RNA extraction and microarray analysis

RNA was collected from LLC tumors either before irradiation (D0) or at day 3, 7, 14, 21 post-irradiation (D3, D7, D14 and D21). Total RNA was quantified by the NanoDrop ND-2000 (Thermo Scientific) and the RNA integrity was assessed using Bioanalyzer 2100 (Agilent). The sample labeling, microarray hybridization and washing were performed based on the manufacturer's standard protocols. In brief, total RNA was transcribed to double strand cDNA, then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned by the Agilent Scanner G2505C (Agilent). The Agilent Mouse Gene Expression 4*44 K v2 Microarray (DesignID: 026,655) was used in this experiment and data analysis was conducted by OE Biotechnology Co. Ltd (Shanghai, China).

Cibersort analysis

The abundance of tumor-infiltrating immune cell subsets was estimated by a deconvolution approach with online analytical tool CIBERSORTx (Cell type identification by estimating relative subsets of known RNA transcripts; https://cibersortx.stanford.edu) [26, 27]. The CIBERSORT LM22 matrix, consisting of 547 genes, transforms gene-expression data of microarray analysis into relative fractions of immune cells phenotypes. CIBERSORT implements Monte Carlo sampling to generate an empirical P-value for the deconvolution. Only cases with a P-value < 0.05, which indicated a reliable estimation of immune cell infiltration, were used for further analysis.

Flow cytometry

Tumor samples were disposed with Tumor Dissociation Kit (Miltenyi Biotec). Then single-cell suspensions from tumors were lysed to remove red blood cells using RBC Lysis/Fixtion Solution (BioLegend) and filtered through a 70 μm MACS SmartStrainer (Miltenyi Biotec). After that, the single-cell suspensions were incubated with fluorescently labeled antibodies (BioLegend) against CD45, CD3, CD4, CD8 and PD-1 at 4℃ for 45 min. For intracellular staining, cells were fixed and permeabilized, and then incubated with TIM-3 (BioLegend), TOX (eBioscience), TCF-1 (BD) at 4℃ for 6 h. Multicolor flow cytometry analysis was conducted with BD Fortessa flow cytometer. Expression level of PD-1 on CD8+ T cells was gated by its low controls of CD8+ T cells from spleen of untreated mice (PD-1low), high controls of cells stained by both anti-TOX and anti-PD-1(PD-1hi) and between them (PD-1int) [15] (Details are provided in the Supplementary Methods section). The proportion of early Tex (CD8+PD-1int) and terminal Tex (CD8+PD-1hi) in CD8+ T cells, the ratio of early to terminal Tex (E/T), and mean fluorescence intensity (MFI) of PD-1 expression on CD8+ T cells were further analyzed using FlowJo software (Treestar).

Radiomics analysis

Tumors were manually delineated on PET/CT images using MIM Maestro Version 7.1.4 (MIM Software), excluding adjacent organs, bone structure and large vessels. Radiomics features were extracted with Imaging biomarker explorer (IBEX) [28], 57 from CT images and 61 from PET images, including first-order features, shape features, and textural features derived from Gray Level Cooccurence Matrix (GLCM) and Gray Level Run Length Matrix (GLRLM) (Table S1). Radiomics features would undergo a two-step selection. First, the feature reproducibility under varying scanning conditions was assessed by test–retest analysis [29, 30], using RIDER Lung CT and RIDER Phantom PET-CT datasets from The Cancer Imaging Archive (TCIA). Concordance correlation coefficient (CCC) was calculated and features with good robustness would be selected for further analysis. Second, with the ICI group as the training set, least absolute shrinkage and selection operator (LASSO) logistic regression was used to select radiomic features significantly correlated with characteristics of T cell exhaustion, such as the infiltrating proportion of early Tex and terminal Tex among CD8+ T cells, E/T, or MFI of PD-1 on CD8+ T cells. Then, significant features were further collected to establish a binary logistic regression model for identifying the level of T cell exhaustion (median proportion of terminal Tex as cutoff). Finally, validation of the model was performed with RT group as external validation set. Concordance index (C-index) and calibration plot were used to evaluate the discriminability and calibration of this model. The goodness-of-fit of model was assessed by Brier score.

Statistical analysis

Data are presented as the mean \(\pm\) SEM. For comparing different time groups, one-way analysis of variance with Bonferroni corrections was applied with two-sided P-values (#P < 0.1, *P < 0.05, **P < 0.01, ***P < 0.001). Statistical analyses were performed using R software 4.1.2 and GraphPad Prism 8.4.3.

Data availability

The data generated in this study are available within the article and its supplementary data files.

Results

CD8+ T cell infiltration increased from 3 to 14 days after ablative irradiation

To assess the immune cell infiltration abundance, we collected LLC tumors at D0, D3, D7, D14 and D21 after ablative irradiation with a single fraction of 20 Gy (Fig. 1A, B) and used CIBERSORT to profile overall immune content in microarray datasets. It was showed that, after ablative irradiation, the tumor-infiltrating CD8+ T cells increased from D3 through the peak at D14, and then declined sharply to a below-baseline level at D21. Immune-promoting cells of innate immune system, such as activated NK cells and M1 macrophages, also exhibited an increasing trend similar to that of CD8+ T cells, peaking at D14 (Fig. 1C). However, the infiltration of immunosuppressive cells, including regulatory T cells (Treg) and M2 macrophages, varied slightly after ablative irradiation (Fig. 1D). Hence, ablative irradiation to the tumor induced a “hot” microenvironment within 2 weeks, with both innate and adaptive immune systems activated, whereas after that it was tending towards a “cold” microenvironment.

Fig. 1
figure 1

Ablative irradiation induced a hot tumor microenvironment within 2 weeks. A Experiment scheme. B Tumor growth of LLC model in RT group and control group. C and D The infiltration of immune-promoting cells (C) and immunosuppressive cells (D) in LLC tumor microenvironment over the time after ablative irradiation. The absolute immune fraction score was produced by CIBERSORT to quantitatively measure the overall abundance of each cell type. #: P < 0.1

Full size image

Anti-PD-L1 antibody reinvigorated CD8+ T cell exhaustion in different degrees

To evaluate the effect of ICI treatment on CD8+ T cell exhaustion and to induce heterogeneous exhaustion status, we administrated five-dose anti-PD-L1 antibody to LLC-mice model (Fig. 2A, B) and performed flow cytometry to capture tumor-infiltrating CD8+ T cells of different exhaustion status (Fig. S1). As comparison to the ICI-resistant LLC model, the same experiment was performed on ICI-responsive B16 model [31]. With a baseline high level of T cell exhaustion (the proportion of terminal Tex in CD8+ T cells ~ 40%), the proportion of early Tex of LLC model did not decrease obviously after anti-PD-L1 intervention, neither did mean MFI of PD-1 expression on CD8+ T cells (Fig. 2C, D, E, F and K). In contrast, B16 model initially possessed a less exhausted T cell population (the baseline proportion of terminal Tex in CD8+ T cells ~ 20%), and the proportion of early Tex as well as mean MFI of PD-1 expression of CD8+ T cells significantly declined after anti-PD-L1 intervention, suggesting a remarkable reinvigoration of T cell exhaustion (Fig. 2G, H, I, J and L). This result is consistent with other previous researches, which have discovered that the exhaustion of tumor-infiltrating CD8+ T cells can be reinvigorated by anti-PD-L1 antibody [32, 33].

Fig. 2
figure 2

Anti-PD-L1 antibody reinvigorated CD8+ T cell exhaustion in different degrees. Flow cytometric analysis of CD8+ T cell exhaustion before and after anti-PD-L1 intervention in LLC and B16 models. A Experiment scheme. B Tumor growth of LLC model and B16 model in ICI group. C The proportion of early and terminal Tex cells in CD8+ T cells of LLC model in ICI group. D The ratio of early-exhausted CD8+ T cells to terminally-exhausted CD8+ T cells (E/T) of LLC model in ICI group. E and F Mean Fluorescence intensity (MFI) of PD-1 expression in CD8+ T cells of LLC model. The data are presented as summary graph (E) and representative plot (F). G The proportion of early and terminal Tex cells in CD8+ T cells of B16 model in ICI group. H E/T of B16 model in ICI group. I and J MFI of PD-1 expression in CD8+ T cells of B16 model. The data are presented as summary graph (I) and representative plot (J). K and L Representative flow cytometric staining of exhausted CD8+ T cells subsets of LLC (K) and B16 models (L). The data shown are representative of three independent experiments (n = 3 per time point) and are presented as the mean ± SEM. *: P < 0.05, ***: P < 0.001

Full size image

CD8+ T cell exhaustion peaked at day 7 through 14 after ablative irradiation

To elucidate the effect of ablative irradiation on CD8+ T cell exhaustion, flow cytometry was further performed at a serial of time points after LLC tumors received a single fraction of 20 Gy (Fig. 3A). The terminal Tex proportion did not change significantly during the first 3 days after irradiation, but then quickly increased and reached the peak at day 7 through 14 (69.44% ~ 76.35%), and sharply dropped to a below-baseline level after that (Fig. 3B, C, and middle row of G). Similar trend was observed in mean MFI of PD-1 expression on CD8+ T cells (Fig. 3D, E).

Fig. 3
figure 3

CD8+ T cell exhaustion peaked at day 7–14 after ablative irradiation and could be visualized by PET radiomics features. Flow cytometric analysis of CD8+ T cell exhaustion after ablative irradiation in LLC model. A Experiment scheme. B The proportion of early and terminal Tex cells in CD8+ T cells. C The ratio of early-exhausted CD8+ T cells to terminally-exhausted CD8+ T cells (E/T). D and E Mean Fluorescence Intensity (MFI) of PD-1 expression in CD8+ T cells. The data are presented as summary graph (D) and representative plot (E). F Representative coronal and cross-sectional PET/CT images for a tumor-bearing mouse. Region of interest (ROI) was manually delineated to cover the entire tumor on fusion images, excluding adjacent organs, bone structure and large vessels (pink line). Radiomics features would be extracted from ROI for further analysis. G Local homogeneity on PET images was negatively correlated with the proportion of terminal Tex cells (CD 8+PD-1hi) in CD8+ T cells. Representative PET pixel images of xenografts (upper row, brighter pixels with higher 18FDG uptake) and corresponding flow cytometric plots (middle row) are showed at each time point, along with radiomics metrics (lower row). The data shown are representative of three independent experiments (n = 3 per time point) and are presented as the mean ± SEM. *P < 0.05, ** P < 0.01, *** P < 0.001

Full size image

Local homogeneity on PET images was negatively correlated with the level of CD8+ T cell exhaustion

To further explore the PET/CT radiomics features which could non-invasively identify CD8+ T cell exhaustion levels, radiomics analysis was performed (Fig. 3F). First, 40 (out of 57) CT (CCC > 0.75) and 9 (out of 61) PET (CCC > 0.65) radiomic features with good robustness were selected through test/retest analysis (Table S2) and then brought into LASSO regression. With ICI groups (including both LLC and B16 models) as the training set, features significantly correlated with characteristics of CD8+ T cell exhaustion were identified (Table 1). Since too small amount of significant CT features were identified, each only exhibiting connection with single exhaustion characteristic, they might contribute little to construct a robust enough model. Therefore, we chose three PET features, which showed strong correlation with multiple exhaustion characteristics, to further establish a binary logistic regression model for determining the level of T cell exhaustion (median proportion of terminal Tex in the training set as cutoff). The proposed model was shown as:

Table 1 Radiomic features significantly correlated with characteristics of CD8+ T cell exhaustion selected through LASSO regression
Full size table
$$T\;exhaustion\;score=-297.597\;\ast\;Inverse\;Variance(\mathrm{GLCM})+178.689\;\ast\;Homogeneity2(\mathrm{GLCM})+1.088\;\ast\;Kurtosis\;(\mathrm{Intensity}\;\mathrm{Histogram})+1.485$$

The radiomics model exhibited good discriminative ability and goodness-of-fit in both training (ICI groups) and validation (RT group) sets, with C-index of 0.818 and 0.776, Brier score of 0.156 and 0.111, respectively. The calibration curves also indicated fine conformity between the predictions and observations in terms of the risk of T cell exhaustion in both training and validation sets (Fig. S2).

Finally, the effect of the radiomics model for assessing the level of T cell exhaustion was visualized through representative pairs of PET pixel images and flow cytometric plots of RT group xenografts (Fig. 3G). Notably, GLCM-inverse variance and GLCM-homogeneity2 on PET images were found to be inversely correlated with the proportion of terminal Tex, indicating more heterogeneous local distribution of 18FDG uptake correlated with higher level of T cell exhaustion.

Discussion

In this study, we described the dynamics of overall infiltration and exhausted subpopulations of tumor-infiltrating CD8+ T cells after ablative irradiation, and developed a PET radiomics model to differentiate T cell exhaustion status, which fitted well in both ICI and irradiation settings. We also visualized the underlying association of more heterogeneous texture on PET images with more progressed T cell exhaustion.

We assumed that when irradiation induces abundant CD8+ T cells to infiltrate the tumors, it might be an optimal timing to integrate ICI therapy when the less exhausted, ICI-responsive CD8+ T cell populations are predominant. Our study highlights an increasing overall infiltration of CD8+ T cells between 3 to 14 days post-irradiation followed by a sharp fall, while terminally exhausted populations significantly predominated CD8.+ T cells during late course of this infiltrating period, i.e. from 7 to 14 days post-irradiation. This result indicated a potential appropriate window for delivering ICI treatment between 3–7 days post-irradiation, which might reasonably explain why the overall response rate was doubled when PD-1 monoclonal antibody was given within 7 days after completion of stereotactic body radiotherapy (SBRT) in patients with metastatic NSCLC [1]

Several preclinical studies demonstrated that ablation doses of 15-25 Gy causes the massive release of antigens and death-associated molecular patterns (DAMP) ligands, and increases T-cell priming in draining lymph nodes, which activates effective antitumor immune response [34,35,36]. One study showed significantly increased infiltration of CD8+ T cells in TME on day 14 after ablative irradiation [37], which is consistent with our results. But the effect of different radiation doses on TME varies. Low-dose irradiation, e.g. 0.5-2 Gy, though insufficient to trigger anticancer response, may recruit tumor-specific CD8+ and CD4+ T lymphocytes into the tumor and reverse tumor immune desertification [38].Though only 20 Gy was investigated in our data, further studies elucidating the effect of more dose-fractionation regimens on T cell infiltration and exhaustion are necessary to help us optimize the combination strategies with ICI.

Growing evidence indicates that, in contrast to the metabolic demands of effector and memory T cells, exhausted T cells undergo metabolic insufficiency with suppressed mitochondrial respiration and glycolysis, involving restricted glucose uptake and use [24, 25]. With the understanding of distinct metabolic characteristics accompanied with T cell exhaustion, it might be a promising way to visualize the exhaustion status through 18FDG uptake distribution on PET images. Our findings demonstrated that local heterogeneity of 18FDG uptake distribution was notably correlated with progressed T cell exhaustion. It could be biologically explained that as early Tex cells developed towards terminal status, their ability of glucose uptake and use was progressively impaired, and thus, the areas where terminal Tex cells predominantly infiltrated might manifest as suppressed 18FDG uptake, decorating less suppressed background where early Tex cells remained dominant to form a heterogeneous landscape of 18FDG uptake distribution.

Recently, new radiotracers have been developed to monitor the distribution of tumor biomarkers in vivo [39] [40], and a phase I study has been conducted to perform CD8 PET imaging of TILs with a radiolabeled anti-CD8 minibody [41]. Such imaging probes might hold great potential for noninvasive PET imaging of specific biomarkers in TME and for timely evaluation of the treatment effect. However, they might be, at least by far, unable to differentiate functional subpopulations of CD8+ T cells since multiple-labelling probes would be more challenging in terms of safety, stability and targeting ability.

Here, we disclosed how the infiltrating CD8+ T cells change, as to the abundance and functionality, in ablatively irradiated TME, which might help to determine “hot” or “cold” TME as well as the optimal timing of ICI intervention. We also proposed a PET radiomics approach to noninvasively visualize the above change, based on the glucose metabolic characteristics of T cell exhaustion, which might serve as a potential solution to clinical situation when TIL biomarkers are unavailable via repeated biopsies. A noninvasive visualization tool spying the TME, cooperated with other minimally invasive, blood-based biomarkers, with the goal to define a clearer and more detailed picture of the tumor immunological parameters, will allow to real-time identify the ICI responders and optimize the combination of ICI with radiotherapy or other TME-modulating therapies [42]. However, the proposed PET radiomics approach to visualize T cell exhaustion would be further modified and verified in patients with NSCLC in future studies before applied in clinical use. And the importance of manipulating T cell exhaustion in TME should be evaluated in the clinical application of cancer immunotherapies.

Conclusion

In summary, we described a previously uncharacterized dynamic atlas of infiltrating CD8+ T cell exhaustion after ablative irradiation, which indicates a potential window for ICI intervention. Basing on the glucose metabolic characteristics associated with T cell exhaustion, a noninvasive PET radiomics approach was developed to evaluate the exhaustion status, which correlates heterogeneous texture of 18FDG uptake distribution with ICI-resistant, progressed T cell exhaustion. This imaging predictor provides a promising solution to timely estimate immune-responsiveness of in-vivo microenvironment and the optimal timing of combined therapy; however, future validation of our findings in patients with NSCLC is needed.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

References

  1. Theelen W, et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–82.

    Article  Google Scholar 

  2. Bauml JM, et al. Pembrolizumab after completion of locally ablative therapy for Oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5(9):1283–90.

    Article  Google Scholar 

  3. Hellmann MD, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.

    Article  CAS  Google Scholar 

  4. Paz-Ares L, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):798–806.

    Article  CAS  Google Scholar 

  5. Sun R, et al. Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? J Immunother Cancer. 2022;10(7):e004848.

    Article  Google Scholar 

  6. Teng MW, et al. Classifying cancers based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75(11):2139–45.

    Article  CAS  Google Scholar 

  7. Parra ER, et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct Intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res. 2016;22(24):6278–89.

    Article  CAS  Google Scholar 

  8. Taube JM, et al. Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.

    Article  Google Scholar 

  9. Feng W, et al. Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach. Ther Adv Med Oncol. 2021;13:1758835920984975.

    Article  CAS  Google Scholar 

  10. Yoneda K, et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019;121(6):490–6.

    Article  CAS  Google Scholar 

  11. McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.

    Article  CAS  Google Scholar 

  12. Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity. 2016;44(5):1052–68.

    Article  CAS  Google Scholar 

  13. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–84.

    Article  CAS  Google Scholar 

  14. Guo X, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24(7):978–85.

    Article  CAS  Google Scholar 

  15. Kim CG, et al. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. J Immunother Cancer. 2021;9(12):e002780.

    Article  Google Scholar 

  16. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures. They Are Data Radiol. 2016;278(2):563–77.

    Google Scholar 

  17. Aerts HJ, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.

    Article  CAS  Google Scholar 

  18. Fried DV, et al. Stage III non-small cell lung cancer: prognostic value of FDG PET quantitative imaging features combined with clinical prognostic factors. Radiology. 2016;278(1):214–22.

    Article  Google Scholar 

  19. Fried DV, et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):834–42.

    Article  Google Scholar 

  20. Huang YQ, et al. Development and validation of a Radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol. 2016;34(18):2157–64.

    Article  Google Scholar 

  21. Tang C, et al. Development of an immune-pathology informed Radiomics model for non-small cell lung cancer. Sci Rep. 2018;8(1):1922.

    Article  Google Scholar 

  22. Sun R, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–91.

    Article  CAS  Google Scholar 

  23. Sun R, et al. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer. 2020;8(2):e001429.

    Article  Google Scholar 

  24. Patsoukis N, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.

    Article  CAS  Google Scholar 

  25. Bengsch B, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45(2):358–73.

    Article  CAS  Google Scholar 

  26. Chen B, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–59.

    Article  CAS  Google Scholar 

  27. Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.

    Article  CAS  Google Scholar 

  28. Zhang L, et al. IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys. 2015;42(3):1341–53.

    Article  Google Scholar 

  29. Balagurunathan Y, et al. Test-retest reproducibility analysis of lung CT image features. J Digit Imaging. 2014;27(6):805–23.

    Article  Google Scholar 

  30. van Timmeren JE, et al. Test-retest data for Radiomics feature stability analysis: generalizable or study-specific? Tomography. 2016;2(4):361–5.

    Article  Google Scholar 

  31. Watanabe T, et al. Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 checkpoint blockade enhances early NK and CD8(+) T-cell-dependent tumor activity. Clin Cancer Res. 2020;26(4):945–56.

    Article  CAS  Google Scholar 

  32. Park J, et al. Immune checkpoint inhibitor-induced Reinvigoration of Tumor-infiltrating CD8(+) T cells is determined by their differentiation status in Glioblastoma. Clin Cancer Res. 2019;25(8):2549–59.

    Article  CAS  Google Scholar 

  33. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856–64.

    Article  CAS  Google Scholar 

  34. Jarosz-Biej M, et al. Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy. Int J Mol Sci. 2019;20(13):3212.

  35. Lee Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.

    Article  CAS  Google Scholar 

  36. Bernstein MB, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–24.

    Article  CAS  Google Scholar 

  37. Filatenkov A, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–39.

    Article  CAS  Google Scholar 

  38. Herrera FG, et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12(1):108–33.

    Article  CAS  Google Scholar 

  39. Lv G, et al. PET Imaging of Tumor PD-L1 Expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61(1):117–22.

    Article  CAS  Google Scholar 

  40. Smit J, et al. PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer. J Nucl Med. 2022;63(5):686–93.

    CAS  Google Scholar 

  41. Farwell MD, et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J Nucl Med. 2022;63(5):720–6.

    CAS  Google Scholar 

  42. Mondini M, Deutsch E. (Chemo)Radiotherapy-Immunotherapy Combinations: time to get tailored? Clin Cancer Res. 2021;27(14):3815–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Shanghai Pujiang Program (18PJD046) and Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190202Z).

Funding

This work was supported by Shanghai Pujiang Program (18PJD046) and Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190202Z).

Author information

Author notes

  1. Ying Zhang and Hui-Hui Hu contributed equally to this work.

Authors and Affiliations

  1. Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai, 200030, China

    Ying Zhang, Hui-Hui Hu, Wu-Yan Xia, Xiao-Long Fu & Wen Yu

  2. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

    Shi-Hong Zhou

  3. Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Yan Zhang

  4. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China

    Jian-Ping Zhang

Authors
  1. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-Hui Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shi-Hong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wu-Yan Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian-Ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-Long Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Ying Zhang and Wen Yu wrote the main manuscript text. Ying Zhang, Hui-Hui Hu, Shi-Hong Zhou and Wu-Yan Xia conducted the experiment. Ying Zhang and Wen Yu searched literature and collected data. Wen Yu and Yan Zhang and Xiao-Long Fu designed the study. Jian-Ping Zhang helped data collection (PET/CT). The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Wen Yu.

Ethics declarations

Ethics approval and consent to participate

The experimental protocol was established and was approved by the Ethics Committee of Shanghai Chest Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig S1.

Representative flow cytometry gating strategy for early-exhausted (PD-1int) and terminally-exhausted (PD-1hi) CD8+ T cells isolated from the tumor of a LLC mouse.

Additional file 2: Fig S2.

Calibration curves of radiomics model.

Additional file 3. Table S1.

Summary of radiomic features.

Additional file 4.  Table S2.

Radiomics features with good robustness.

Additional file 5.

Supplementary Methods.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Hu, HH., Zhou, SH. et al. PET-based radiomics visualizes tumor-infiltrating CD8 T cell exhaustion to optimize radiotherapy/immunotherapy combination in mouse models of lung cancer. Biomark Res 11, 10 (2023). https://doi.org/10.1186/s40364-023-00454-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40364-023-00454-z

Keywords

Biomarker Research

ISSN: 2050-7771

Contact us